Dabrafenib is the second agent in the therapeutic class of selective BRAF inhibitors, and has shown efficacy in a BREAK-3, randomized phase III trial with improvements in progression-free survival and response rates. Differences in the safety profile exist compared with vemurafenib, but the future lies in combinatorial strategies and improved patient selection. Read more here.
Study mentioned: Tawbi HA, Kirkwood JM. Targeted therapies: BREAKing a path for progress-dabrafenib confirms class effect. Nat Rev Clin Oncol. 2012 Aug 14;9(9):496-7. PMID: 22889973
No comments:
Post a Comment